Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.…
AORT Q3 2026 deep dive: stent graft growth and NEXUS launch preparations shape outlook
Artivion (NYSE: AORT) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,800 employees.
The shares were at 18.16 USD on 20 November 2026, down 59.6% over 52 weeks. Its 52-week range is 18.11 USD to 48.25 USD, and it trades at the bottom of that range.
Its market capitalisation is 886.02M USD.
Artivion reports return on equity of 2.2%, an operating margin of 7.6% and revenue up 9.2% year over year.
Its debt exceeds its cash by 358.63M USD, a debt-to-equity ratio of 0.57. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 38.47 USD is 111.8% above the current price. The next earnings report is expected on 11 February 2027.